DOI: 10.2217/fon-2022-1315 ISSN: 1479-6694

A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries

Noemi Reguart, Maurice Pérol, Diego Cortinovis, Stephen Puntis, Katarina Öhrling, Olia Archangelidi, Karly S Louie, Fiona Blackhall, Martin Sebastian
  • Cancer Research
  • Oncology
  • General Medicine

Aim: To investigate changes in treatment patterns in extensive-stage small-cell lung cancer (ES-SCLC) in France, Germany, Italy, Spain and the UK (EU5) between 2018 and 2021. Methods: Cross-sectional data from an oncology database were analyzed retrospectively. Results: Of 5832 eligible patients, 88.4% had stage IV disease at diagnosis. Among patients receiving first-line treatment, 91.8% (1079 /1176) received the platinum-etoposide (PE) combination in 2018 which decreased to 42.3% (509/1203) by 2021. Usage of the PE-atezolizumab combination increased from 0 to 41.2% during the same timeframe. Topotecan monotherapy remained the most widely used second-line treatment regardless of patients' platinum sensitivity. Conclusion: The first-line standard of care for ES-SCLC has evolved in EU5 with the PE-atezolizumab/durvalumab combination gradually superseding PE usage.

More from our Archive